Dr. Mengyu Lu leads Kirkland & Ellis’s Asia capital markets practice from its Hong Kong office. With a specialization in Hong Kong IPOs, SPACs, preIPO financings, follow-on offerings, M&A, and post‑listing compliance, she is a trusted legal advisor to issuers, investment banks, private equity and venture capital firms across the region. Her expertise notably spans the “new economy” sectors—healthcare, biotech, semiconductors, AI, TMT, and consumer—working with clients like NIO, Will Semiconductor, Kelun Biotech, Super Hi, ZG Group, and more. Dr. Lu began her legal journey at Freshfields Bruckhaus Deringer (2008–2010), joined Kirkland & Ellis in 2011, made partner in 2014, moved to Sidley Austin (2015–2021), and re-joined Kirkland in early 2021. A distinguished capital markets specialist with a Ph.D., Dr. Mengyu Lu combines academic depth, elite law firm experience, and landmark deal credentials. As one of Asia’s leading lawyers in equity and debt markets, she continues to shape the region’s capital market landscape, forging transformative public listings and financing deals. EDDING GROUP COMPANY LTD TO ACQUIRE GENOR BIOPHARMA HOLDINGS LIMITED DR. MENGYU LU Partner - Kirkland Ellis ABOUT DR. MENGYU LU CHINA 62 Finance Monthly Deal Maker Awards 2025.
RkJQdWJsaXNoZXIy Mjk3Mzkz